Skip to main content

Abivax’s Covid-19 Phase 2b/3 miR-AGE trial with ABX464 declared Research National Priority by the French government’s Clinical Trial Council

[image_slider_no_space on_click=”prettyphoto” height=”600″ navigation_style=”light” images=”940,950,954,952,953,951″]